论文部分内容阅读
目的观察VMTP方案治疗难治性或复发性多发性骨髓瘤患者的临床疗效。方法对13例难治性或复发性多发性骨髓瘤患者分别或先后采用MP方案及VMCP方案进行化疗,每隔4周施行一次,观察疗效及药物毒副作用。结果2例获得部分缓解,6例出现进步,5例无效,总有效率为61.5%;有显著性统计学意义(P<0.001)。结论THP为主的VMTP化疗方案治疗难治性或复发性多发性骨髓瘤安全有效,值得临床进一步推广应用。
Objective To observe the clinical effect of VMTP regimen in patients with refractory or recurrent multiple myeloma. Methods Thirteen patients with refractory or recurrent multiple myeloma were treated with MP regimen and VMCP regimen respectively and once every 4 weeks to observe the curative effect and drug side effects. Results Two patients were partially relieved, six patients showed improvement, and five patients were ineffective. The total effective rate was 61.5%. There was a significant statistical significance (P <0.001). Conclusions THP-based VMTP chemotherapy is safe and effective in the treatment of refractory or recurrent multiple myeloma, which is worth further clinical application.